Maternal Vaccination vs Nirsevimab Use and RSV Infection Among Full-Term Infants

Дата публикации: 24-10-2026 00:00:00

This cohort study estimates the relative product effectiveness of material respiratory syncytial virus (RSV) vaccination compared with infant nirsevimab for infection and hospitalization among full-term infants born in the 2023 to 2025 RSV seasons.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	RSV Immunization With RSVpreF and Nirsevimab	0	13.58	01-08-2026
2	Estudios en vida real respaldan la eficacia de nirsevimab frente a VRS en la reducción de ingresos de lactantes	0	3.44	19-10-2026
3	<![CDATA[Clesrovimab Given in 1st and 2nd RSV Seasons for At-Risk Infants ]]>	0	10.71	03-10-2026
4	Moms who receive COVID, flu vaccines during pregnancy more likely to vaccinate their babies, study says	0	8.92	16-07-2026
5	Shared Clinical Decision-Making for Rotavirus Vaccination in Infants	0	11.57	26-10-2026
6	One immunization may protect newborns against 2 serious diseases	0	18.3	24-07-2026
7	CDPH Issues Immunization Recommendations for 2026-27 Respiratory Virus Season	0	27.62	05-09-2026
8	<![CDATA[Maternal Vaccination Shown to Protect Against K Pneumoniae Neonatal Sepsis]]>	0	8.6	20-10-2026
9	Flu Vaccine Remains Highly Effective Against Pediatric Mortality	0	7.79	18-08-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 12.96. Источник: jamanetwork.com.